Clinical Trial

Renal Impairment Pharmacokinetics (PK) Trial of Afabicin

Name: Renal Impairment Pharmacokinetics (PK) Trial of Afabicin — clinical trial record (NCT07758608)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Not Yet Recruiting Phase 1

View on ClinicalTrials.gov →

Summary

The primary purpose of this study is to assess the effect of renal impairment on the PK of afabicin desphosphono after a single oral 80 milligrams (mg) or intravenous (IV) 55 mg dose of afabicin.

Trial Details

NCT Number	NCT07758608
Lead Sponsor	Debiopharm International SA
Conditions	Renal Impairment
Enrollment	60 participants
Start Date	2026-08
Primary Completion	2027-12 (estimated)
Study Completion	2028-02 (estimated)
Updated on ClinicalTrials.gov	2026-08-11